Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Toloue Masoud | President & CEO | Jun 13 | Sale | 15.27 | 5,564 | 84,955 | 81,701 | Jun 14 04:12 PM | Fry John J | General Counsel & Secretary | Jun 02 | Sale | 17.47 | 378 | 6,605 | 38,459 | Jun 03 04:19 PM | HRUSOVSKY E KEVIN | Executive Chairman | Jun 02 | Sale | 17.47 | 712 | 12,441 | 911,209 | Jun 03 04:19 PM | HRUSOVSKY E KEVIN | Executive Chairman | May 02 | Sale | 22.36 | 649 | 14,515 | 911,921 | May 03 04:34 PM | Fry John J | General Counsel & Secretary | May 02 | Sale | 22.36 | 429 | 9,595 | 38,837 | May 03 04:25 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Apr 01 | Sale | 29.79 | 868 | 25,860 | 886,976 | Apr 05 04:03 PM | Mattoon Dawn | Sr. VP, Diagnostics | Apr 01 | Sale | 29.79 | 261 | 7,776 | 36,876 | Apr 05 04:02 PM | Fry John J | General Counsel & Secretary | Apr 01 | Sale | 29.79 | 524 | 15,611 | 30,229 | Apr 05 04:02 PM | Roskey Mark T. | SVP, Strategic Partnerships | Apr 01 | Sale | 29.79 | 171 | 5,095 | 22,325 | Apr 05 04:03 PM | Duffy David C. | SVP R&D and CTO | Mar 23 | Sale | 30.00 | 3,266 | 97,980 | 54,730 | Mar 28 05:02 PM | Fry John J | General Counsel & Secretary | Mar 01 | Sale | 31.46 | 371 | 11,671 | 30,753 | Mar 03 05:00 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Mar 01 | Sale | 31.46 | 589 | 18,530 | 887,844 | Mar 03 05:01 PM | Roskey Mark T. | SVP, Strategic Partnerships | Mar 01 | Sale | 31.46 | 166 | 5,222 | 22,496 | Mar 03 05:01 PM | Mattoon Dawn | Sr. VP, Diagnostics | Mar 01 | Sale | 31.46 | 267 | 8,399 | 37,137 | Mar 03 05:00 PM | Fry John J | General Counsel & Secretary | Feb 09 | Sale | 34.97 | 481 | 16,820 | 31,124 | Feb 09 05:12 PM | Roskey Mark T. | SVP, Strategic Partnerships | Feb 09 | Sale | 34.97 | 292 | 10,211 | 22,662 | Feb 09 05:13 PM | Mattoon Dawn | Sr. VP, Diagnostics | Feb 09 | Sale | 34.97 | 318 | 11,120 | 37,404 | Feb 09 05:12 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Feb 09 | Sale | 34.97 | 1,364 | 47,697 | 888,433 | Feb 09 05:10 PM | Duffy David C. | SVP R&D and CTO | Feb 04 | Sale | 30.91 | 3,266 | 100,952 | 57,996 | Feb 04 04:01 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Feb 02 | Sale | 31.46 | 589 | 18,530 | 889,797 | Feb 04 04:00 PM | Mattoon Dawn | Sr. VP, Diagnostics | Feb 02 | Sale | 31.46 | 267 | 8,399 | 37,722 | Feb 04 04:00 PM | Roskey Mark T. | SVP, Strategic Partnerships | Feb 02 | Sale | 31.46 | 166 | 5,222 | 22,954 | Feb 04 04:01 PM | Fry John J | General Counsel & Secretary | Feb 02 | Sale | 31.46 | 371 | 11,671 | 31,605 | Feb 04 04:00 PM | Duffy David C. | SVP R&D and CTO | Jan 31 | Sale | 30.00 | 3,266 | 97,980 | 61,262 | Jan 31 04:12 PM | Duffy David C. | SVP R&D and CTO | Jan 03 | Option Exercise | 2.59 | 41,246 | 106,704 | 64,528 | Jan 05 04:04 PM | Mattoon Dawn | Sr. VP, Diagnostics | Jan 03 | Sale | 41.91 | 355 | 14,877 | 37,989 | Jan 05 04:06 PM | Roskey Mark T. | SVP, Strategic Partnerships | Jan 03 | Sale | 41.91 | 149 | 6,244 | 23,120 | Jan 05 04:06 PM | Fry John J | General Counsel & Secretary | Jan 03 | Sale | 41.91 | 352 | 14,751 | 31,976 | Jan 05 04:06 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Jan 03 | Sale | 41.91 | 3,715 | 155,683 | 890,386 | Jan 05 04:06 PM | Duffy David C. | SVP R&D and CTO | Dec 29 | Sale | 40.71 | 1,667 | 67,864 | 23,282 | Dec 30 04:57 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Dec 01 | Sale | 40.29 | 3,710 | 149,477 | 894,101 | Dec 03 04:20 PM | Roskey Mark T. | SVP, Strategic Partnerships | Dec 01 | Sale | 40.29 | 147 | 5,923 | 23,269 | Dec 03 04:19 PM | Fry John J | General Counsel & Secretary | Dec 01 | Sale | 40.29 | 350 | 14,101 | 32,328 | Dec 03 04:18 PM | Mattoon Dawn | Sr. VP, Diagnostics | Dec 01 | Sale | 40.29 | 353 | 14,222 | 38,344 | Dec 03 04:18 PM | Duffy David C. | SVP R&D and CTO | Nov 19 | Sale | 45.54 | 1,667 | 75,915 | 24,949 | Nov 22 06:18 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Nov 10 | Sale | 55.18 | 5,000 | 275,897 | 897,811 | Nov 10 04:06 PM | Mattoon Dawn | Sr. VP, Diagnostics | Nov 05 | Option Exercise | 19.12 | 10,718 | 204,928 | 47,232 | Nov 08 04:26 PM | Mattoon Dawn | Sr. VP, Diagnostics | Nov 05 | Sale | 57.28 | 8,535 | 488,851 | 38,697 | Nov 08 04:26 PM | Mattoon Dawn | Sr. VP, Diagnostics | Nov 04 | Sale | 57.00 | 1 | 57 | 36,514 | Nov 08 04:26 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Nov 02 | Sale | 52.61 | 3,505 | 184,385 | 902,811 | Nov 04 04:19 PM | Roskey Mark T. | SVP, Strategic Partnerships | Nov 02 | Sale | 52.61 | 139 | 7,312 | 23,416 | Nov 04 04:20 PM | Fry John J | General Counsel & Secretary | Nov 02 | Sale | 52.61 | 331 | 17,412 | 32,678 | Nov 04 04:19 PM | Mattoon Dawn | Sr. VP, Diagnostics | Nov 02 | Sale | 52.61 | 333 | 17,518 | 36,515 | Nov 04 04:19 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Oct 22 | Sale | 50.70 | 5,000 | 253,520 | 906,316 | Oct 22 05:48 PM | Duffy David C. | SVP R&D and CTO | Oct 15 | Sale | 51.47 | 1,667 | 85,800 | 26,616 | Oct 19 04:00 PM | Roskey Mark T. | SVP, Strategic Partnerships | Oct 01 | Sale | 51.20 | 143 | 7,322 | 23,555 | Oct 05 04:02 PM | Mattoon Dawn | Sr. VP, Diagnostics | Oct 01 | Sale | 51.20 | 342 | 17,511 | 36,848 | Oct 05 04:02 PM | Fry John J | General Counsel & Secretary | Oct 01 | Sale | 51.20 | 340 | 17,408 | 33,009 | Oct 05 04:02 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Oct 01 | Sale | 51.20 | 3,594 | 184,015 | 911,316 | Oct 04 04:02 PM | HRUSOVSKY E KEVIN | Chairman and CEO | Sep 30 | Sale | 49.09 | 5,000 | 245,449 | 914,910 | Oct 04 04:02 PM | Duffy David C. | SVP R&D and CTO | Sep 22 | Sale | 47.72 | 1,667 | 79,549 | 28,283 | Oct 04 04:09 PM | HRUSOVSKY E KEVIN | Chairman, President & CEO | Sep 02 | Sale | 49.66 | 5,000 | 248,307 | 919,910 | Sep 03 04:01 PM | HRUSOVSKY E KEVIN | Chairman, President & CEO | Sep 01 | Sale | 49.92 | 3,709 | 185,158 | 924,910 | Sep 03 04:01 PM | Mattoon Dawn | Sr. VP, Diagnostics | Sep 01 | Sale | 49.92 | 353 | 17,622 | 37,190 | Sep 03 04:01 PM | Fry John J | General Counsel & Secretary | Sep 01 | Sale | 49.92 | 350 | 17,472 | 33,349 | Sep 03 04:01 PM | Roskey Mark T. | SVP, Strategic Partnerships | Sep 01 | Sale | 49.92 | 147 | 7,338 | 23,698 | Sep 03 04:01 PM | Duffy David C. | SVP R&D and CTO | Aug 20 | Sale | 46.13 | 1,667 | 76,899 | 29,950 | Aug 20 04:08 PM | HRUSOVSKY E KEVIN | Chairman, President & CEO | Aug 16 | Sale | 47.33 | 5,000 | 236,669 | 928,619 | Aug 18 04:19 PM | HRUSOVSKY E KEVIN | Chairman, President & CEO | Aug 03 | Sale | 53.79 | 3,648 | 196,219 | 933,619 | Aug 03 09:34 PM | Fry John J | General Counsel & Secretary | Aug 03 | Sale | 53.79 | 344 | 18,503 | 33,699 | Aug 03 09:32 PM | Mattoon Dawn | Sr. VP, Diagnostics | Aug 03 | Sale | 53.79 | 346 | 18,611 | 37,543 | Aug 03 09:31 PM | Roskey Mark T. | SVP, Strategic Partnerships | Aug 03 | Sale | 53.79 | 145 | 7,799 | 23,845 | Aug 03 09:29 PM | HRUSOVSKY E KEVIN | Chairman, President & CEO | Jul 29 | Sale | 54.08 | 5,000 | 270,420 | 937,267 | Jul 30 04:39 PM | Duffy David C. | SVP R&D and CTO | Jul 14 | Sale | 57.77 | 1,667 | 96,303 | 31,617 | Jul 14 05:08 PM | HRUSOVSKY E KEVIN | Chairman, President & CEO | Jul 13 | Sale | 57.45 | 5,000 | 287,265 | 942,267 | Jul 14 05:03 PM |
|